A Comparative Study to Assess Efficacy of Intralesional MMR Vaccine and Intralesional Vitamin D3 in Treatment of Warts

NACompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

June 1, 2020

Primary Completion Date

January 15, 2021

Study Completion Date

January 30, 2021

Conditions
Verruca Viral
Interventions
DRUG

Measles-Mumps-Rubella Vaccine

Group A patients will receive intralesional injection of upto 0.5 mL of reconstituted MMR vaccine into a single or a maximum of 5 warts at a time in case of multiple warts. Intralesional injection will be given every three weeks for a maximum of 5 doses or until complete resolution, whichever is earlier.

DRUG

Vit D

Group B patients will receive a maximum of 0.5 mL Inj. Vitamin D3 (600,000 IU; 15mg/ml) in each session after injection of IL lignocaine with 31 G insulin syringe. In cases of multiple warts, a maximum of 5 warts will be injected at a time. The session will be done at 3 weekly intervals for a maximum of 5 sessions or until complete resolution of warts, whichever is earlier

Trial Locations (1)

7053

BP Koirala Institute of Health Sciences, Dharān

All Listed Sponsors
collaborator

Nepal Health Research Council

OTHER_GOV

lead

B.P. Koirala Institute of Health Sciences

OTHER

NCT04428359 - A Comparative Study to Assess Efficacy of Intralesional MMR Vaccine and Intralesional Vitamin D3 in Treatment of Warts | Biotech Hunter | Biotech Hunter